Eupraxia Pharmaceuticals Website, Blog & Press Pages

Eupraxia Pharmaceuticals Website, Blog & Press Pages - aVenture Research

Library

eupraxiapharma.comCrawled Nov 9, 2026

3 pages

Clinical Research/clinical-research
Eupraxia is currently pursuing the clinical development of EP-104GI for the treatment of eosinophilic esophagitis (EoE) and EP-104IAR for knee osteoarthritis (OA).
Extended-release drug delivery/our-science-diffusphere-extended-release-technology
Eupraxia Pharmaceuticals’ DiffuSphere technology enables precise, localized drug delivery with fewer side effects and improved therapeutic outcomes.
Patients/patients
Eosinophilic esophagitis (EoE) is a chronic inflammatory condition of the esophagus, causing symptoms like difficulty or pain when swallowing.

6 pages

EP-104IAR (Long-Acting Intra-Articular Injection of Fluticasone Propionate): Results from a Phase 2 Randomized, Double-blind, Vehicle-Controlled Trial in 318 Subjects with Knee Osteoarthritis/publication/ep-104iar-long-acting-intra-articular-injection-of-fluticasone-propionate-results-from-a-phase-2-randomized-double-blind-vehicle-controlled-trial-in-318-subjects-with-knee-osteoarthritis
Initial Results from RESOLVE, a Phase 1b/2a Dose-Escalation Study of EP-104GI (Extended-Release Fluticasone Propionate Intra-Esophageal Injection) for Eosinophilic Esophagitis/publication/initial-results-from-resolve-a-phase-1b-2a-dose-escalation-study-of-ep-104gi-extended-release-fluticasone-propionate-intra-esophageal-injection-for-eosinophilic-esophagitis
Initial Results From RESOLVE, an Ongoing Phase 1b/2a Dose-escalation Study of EP-104GI (Long-acting Fluticasone Propionate Injectable Suspension) For Eosinophilic Esophagitis/publication/initial-results-from-resolve-an-ongoing-phase-1b-2a-dose-escalation-study-of-ep-104gi-long-acting-fluticasone-propionate-injectable-suspension-for-eosinophilic-esophagitis
Pharmacokinetic Profile of Intra-articular Fluticasone Propionate Microparticles in Beagle Dog Knees/publication/pharmacokinetic-profile-of-intra-articular-fluticasone-propionate-microparticles-in-beagle-dog-knees

4 pages

Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI/eupraxia-pharmaceuticals-announces-sustained-positive-treatment-outcomes-in-patients-with-eosinophilic-esophagitis-eoe-after-nine-months-of-receiving-ep-104gi
Eupraxia Pharmaceuticals reports positive treatment outcomes from its Phase 1b/2a RESOLVE trial evaluating EP-104GI for eosinophilic esophagitis.
Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results/eupraxia-pharmaceuticals-reports-first-quarter-2025-financial-results
Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025/eupraxia-pharmaceuticals-to-host-virtual-kol-event-to-discuss-the-phase-1b-2a-resolve-study-of-ep-104gi-for-the-treatment-of-eosinophilic-esophagitis-eoe-on-may-9-2025
Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May/eupraxia-pharmaceuticals-to-present-at-investor-and-scientific-conferences-in-april-and-may
Eupraxia Pharmaceuticals announces upcoming presentations by its management and scientific teams at investor and scientific conferences.

6 pages

Careers/careers
Eupraxia Pharmaceuticals seeks innovative professionals to join its team in advancing patient care and research.
Director, External Corporate Communications/career/director-external-corporate-communications
Hybrid Archives/career-type/hybrid
Office Archives/career-type/office

6 pages

Dr. Albert J Bredenoord/team-member/dr-albert-j-bredenoord
Albert J. (Arjan) Bredenoord is a consultant gastroenterologist at the Amsterdam University Medical Center and professor of Neurogastroenterology & Motility at the University of Amsterdam.
Dr. Donna Griebel/team-member/dr-donna-griebel
Donna Griebel is a regulatory consultant at Griebel and Rosebraugh Consulting, LLC, having previously served as Division Director of the Division of Gastroenterology and Inborn Errors Products at the FDA.
Dr. Evan Dellon/team-member/dr-evan-dellon
Evan S. Dellon directs the Center for Gastrointestinal Biology and Disease Clinical Research Core and the UNC Center for Esophageal Diseases and Swallowing at the University of North Carolina School of Medicine.
Dr. Nirmala Gonsalves/team-member/dr-nirmala-gonsalves
Dr. Gonsalves is a professor of medicine in the Division of Gastroenterology & Hepatology at Northwestern University Feinberg School of Medicine, specializing in eosinophilic gastrointestinal diseases (EGIDs).

1 page

About us/about-us
Eupraxia is a clinical-stage biotechnology company developing targeted therapies designed to deliver the right drug dose, in the right place, for the right amount of time.

1 page

Contact/contact
CONTACT US Get in Touch Eupraxia Pharmaceuticals 2198 Yukon St, Vancouver, BC, V5Y 3P1 Canada 250-590-3968 info@eupraxiapharma.com Investor Relations Kevin Gardner 617-283-2856 investors@eupraxiapharma.com

1 page

Homepage/
Eupraxia is a clinical-stage biotechnology company developing targeted therapies that leverage a proprietary extended-release delivery system.

3 pages

Privacy Choices/privacy-choices
Privacy policy/politique-de-confidentialit
Privacy Policy/privacy-policy
Eupraxia Pharmaceuticals commits to providing exceptional service to patients, healthcare professionals, research partners, and investors while handling personal information responsibly.

1 page

Terms of Use/terms-of-use
The Terms of Use outline the conditions for accessing and using eupraxiapharma.com, governed by Eupraxia Pharmaceuticals Inc.